The purpose of this study is to determine the effectiveness of a new ultrasound technique to detect cancer and/or other abnormalities in lymph nodes, small bean-shaped structures that are part of the body's immune system. Participants in this study will have at least one lymph node that may be larger than normal. 

The purpose of this study is to find out what effects an immunotherapy drug, called pembrolizumab, combined with a radioactive drug, called lutetium Lu 177 dotatate (Lutathera®) have on Merkel cell carcinoma.

The purpose of this study is to test the safety and effectiveness of the experimental combination of tazemetostat with chimeric antigen receptor t-cell (CAR T) cell therapy, and see what effects it has on lymphoma. An additional purpose of this study is to understand what side effects people may have when they receive both drugs together.

The purpose of the study is to evaluate the potential interaction between an investigational drug combination of ASTX727 and venetoclax, and evaluate the safety and potential benefits when the study drugs are taken together for acute myeloid leukemia (AML). This study will include adults who have newly diagnosed AML who are age 75 years or older, or who have other medical conditions that don’t allow the use of intensive chemotherapy.
   

Sometimes tumors develop resistance to chemotherapy and the body stops responding to the drug and the cancer grows or spreads. The tumor may use cortisol, a steroid hormone naturally produced in the body, to develop chemotherapy resistance. Cortisol plays a role in controlling different processes throughout the body, including the body’s immune response (the reaction of the cells and fluids in the body to the presence of a foreign substance, such as a virus, an infection or cancer).

This clinical trial is for men and women with newly diagnosed Acute Myeloid Lymphoma (AML) who are not eligible for intensive chemotherapy.
   
The purpose of this study is to evaluate the safety and effectiveness of the addition of an experimental drug, magrolimab, in combination with venetoclax and azacitidine compared to venetoclax and azacitidine alone.
   
Experimental means that magrolimab has not yet been approved by the U.S. Food and Drug Administration (FDA).
   

This study is being conducted to learn more about the effects and safety of the investigational/experimental study drug MGL-3196 (resmetirom) and compare the study drug with placebo in men or women who have been diagnosed with Non-Alcoholic Steatohepatitis (NASH). 
   
An investigational/experimental study drug is one that has not been approved by the Food and Drug Administration (FDA). 
   

This clinical trial is for adult participants who have myelofibrosis for which standard therapy has proven ineffective, or for those who cannot tolerate the standard therapy or are not able to receive the standard therapy.
   

The purpose of this study is to learn about changes in brain function, thoughts, feelings, and behavior that occur during treatment for depression and suicidal ideation.

Suicidality in mid- and late life is characterized with abnormalities in the Positive Valence System (PVS). The aim of the study is to examine if exposure to meaningful social rewards during psychotherapy engages PVS circuitry and improves mid- and late-life suicidality among depressed older adults.

This is a research study to evaluate the safety and tolerability of an experimental drug called TVB-2640 in combination with Enzalutamide for men with metastatic castration resistant prostate cancer (mCRPC) whose disease has progressed while taking androgen-deprivation therapy (ADT). ADT is the primary treatment method for mCRPC. This study will find the highest dose of TVB-2640 that can be given with Enzalutamide without causing severe side effects.